title: The TeGenero incident and the Duff Report conclusions: a series of unfortunate events or an avoidable event?
authors.affiliation: PreClinical Sciences, Taligen Therapeutics, Cambridge, Massachusetts 02142, USA. chorvath@taligentherapeutics.com
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Horvath
authors.forename: Mark N
authors.initials: MN
authors.lastname: Milton
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018106:CD28 Antigens / Q000378:metabolism; D017321:Clinical Trials, Phase I as Topic / Q000379:methods / Q000592:standards*; D064420:Drug-Related Side Effects and Adverse Reactions; D006287:Health Planning Guidelines; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D008213:Lymphocyte Activation / Q000276:immunology; D010599:Pharmacokinetics; D010600:Pharmacology / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018106:CD28 Antigens; C509303:TGN-1412